Ikena Oncology Inc

NASDAQ:IKNA USA Biotechnology
Market Cap
$59.90 Million
Market Cap Rank
#29127 Global
#9665 in USA
Share Price
$1.43
Change (1 day)
+4.38%
52-Week Range
$1.03 - $1.47
All Time High
$32.00
About

Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more

Ikena Oncology Inc - Asset Resilience Ratio

Latest as of June 2025: 29.61%

Ikena Oncology Inc (IKNA) has an Asset Resilience Ratio of 29.61% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$37.35 Million
Cash + Short-term Investments
Total Assets
$126.17 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2024)

This chart shows how Ikena Oncology Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Ikena Oncology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $37.35 Million 29.61%
Total Liquid Assets $37.35 Million 29.61%

Asset Resilience Insights

  • Very High Liquidity: Ikena Oncology Inc maintains exceptional liquid asset reserves at 29.61% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Ikena Oncology Inc Industry Peers by Asset Resilience Ratio

Compare Ikena Oncology Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Ikena Oncology Inc (2021–2024)

The table below shows the annual Asset Resilience Ratio data for Ikena Oncology Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 60.06% $84.99 Million $141.51 Million +31.13pp
2023-12-31 28.93% $55.57 Million $192.09 Million -27.40pp
2022-12-31 56.33% $97.03 Million $172.26 Million --
2021-12-31 0.00% $0.00 $247.88 Million --
pp = percentage points